FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101. Beyond its mental health applications, NRX-101 shows promise as a non-opioid ...
RVA MAG8h
Can Ketamine Really Heal Trauma? Richmond Therapists Share Their Insights
This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...
IFLScience14h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Psychology Today17h
Mental Health Treatment and the Brain
Scientists have explored whether cognitive behavioral therapy (CBT), a widely used treatment for anxiety disorders and depression, improves symptoms in part by altering the function of the ...